Dr. Dan T. La, MD

Dr. La practices at Dan La MD INC in Tujunga, California.

Dr. La's NPI, 1437178274, was assigned on July 19, 2006. Dr. La graduated from American University of the Caribbean School of Medicine in 2001. Dr. La's California license number on file is A84795.

Dr. La's primary practice is Dan La MD INC, at 6673 W Foothill Blvd, Tujunga, CA 91042. The practice phone is (818) 265-2250.

Dr. La's primary practice is Dan La MD INC in Tujunga, California. Dr. La is also affiliated with USC Verdugo Hills Hospital. The medical group on file is Foothill Arthritis Clinic. Dmand AI also links Dr. La to 4 more hospitals and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. La practices, 7 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. La's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. La is board certified in rheumatology by the American Board of Internal Medicine. Dr. La has a license on file in California.

Dmand AI lists arteritis, arthritis, fluid in a joint, gout, joint arthropathy, joint cyst, joint pain and lupus among the conditions Dr. La treats.

CMS data shows 27,463 Medicare services from Dr. La across 21 procedure codes in 2024, for 830 Medicare patients. Medicare paid $981,133 for them.

CMS counts 830 Medicare patients who saw Dr. La in 2024. The largest group is 65 to 74, with 364 patients. 75% of them have arthritis, and 75% have high blood pressure. 67% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. La's median patient age at 61, with 81% women.

In 2024, Dr. La wrote 9,737 Medicare Part D claims for 877 patients. 86% of them were for generic drugs. CMS names the drug for 9,446 of them, across 71 drugs with 11 or more claims each, at $4,730,413 in total drug cost. In 2023, CMS named 7,861 claims across 68 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. La for performance year 2024, reported individually. Dr. La accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. La, published from 2014 to 2022. Dr. La's most frequent co-authors are Suneet Grewal, MD, Brian David Lamoreaux, MD and Karon R. Locicero, MD.

Dmand AI links Dr. La to 6 clinical trials. Conditions studied include Arthritis, Rheumatoid, Lupus Erythematosus, Systemic and Connective Tissue Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. La that name 3 trials.

CMS Open Payments shows 2,588 general payments to Dr. La from 52 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. Abbvie Inc. paid the most, $39,461. It also lists 5 research payments totaling $370 from 2020 to 2024, naming 3 clinical trials.

Dmand AI lists 2 awards for Dr. La, most recently CMS Stage 1 2012 in 2012.

Dr. La graduated from American University of the Caribbean School of Medicine in 2001. Dr. La is a member of ACP and ACR.

Dr. La is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.